Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-130417, MOP-102758)
University of Victoria-Genome BC Proteomics Centre (204PRO, 214PRO)
Max Planck Society and DFG (CRC 1080, CRC 902)
European Research Council under the European Union’s Horizon 2020 research and innovation program (743216 to EMS, 727264 (EPIPHARM))
Spanish Ministerio de Economia y Competitividad (BFU2013-47064-P, BFU2016-78232-P, SAF2014-55000-R)
Instituto de Salud Carlos III and co-funded by European Union (PI15/00663)
Terry Fox Research Institute Program Project (TFRI #1039)
Canadian Cancer Society Research Institute (CCSRI #703489)
Health and Science Departments of the Catalan Government (AGAUR [2014SGR633])
Received: 18 May 2019
Accepted: 22 August 2019
First Online: 10 October 2019
Ethics approval and consent to participate
: The experimental procedures were in accordance with all legislations defined by the European Union and approved by the local ethics committees from Barcelona (UB-IDIBELL) and Toulouse (permit number: 04-U1043-DG-06).
: Not applicable.
: The authors declare that they have no competing interests.